{"entity":{"id":"da-trial-evoke","kind":"trial","name":"EVOKE (semaglutide in early Alzheimer’s)","aka":[],"tldr":"EVOKE tests oral semaglutide in early Alzheimer’s disease. Existing diabetes/obesity labels are not a dementia indication.","summary":"Phase 3, randomised, placebo-controlled. Cognition outcomes and safety for Alzheimer’s use are still under study. Not for self-directed dementia treatment.","status":"recruiting","asOf":"2026-09-21","links":[{"label":"ClinicalTrials.gov NCT04777396","url":"https://clinicaltrials.gov/study/NCT04777396"}],"tags":["dementia-atlas"],"related":[],"cancers":["alzheimers-disease","mild-cognitive-impairment"],"sections":[],"technologies":[],"targets":[],"drugs":["da-semaglutide-evoke"],"companies":["da-novo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04777396","phase":"3","setting":"Early Alzheimer’s disease","sponsor":"Novo Nordisk","outcomes":[]},"route":"/trials/da-trial-evoke/","neighbours":{"cancer":[{"id":"alzheimers-disease","kind":"cancer","name":"Alzheimer’s disease","route":"/diagnoses/alzheimers-disease/"},{"id":"mild-cognitive-impairment","kind":"cancer","name":"Mild cognitive impairment","route":"/diagnoses/mild-cognitive-impairment/"}],"drug":[{"id":"da-semaglutide-evoke","kind":"drug","name":"Semaglutide (EVOKE programme)","route":"/drugs/da-semaglutide-evoke/"}],"company":[{"id":"da-novo","kind":"company","name":"Novo Nordisk","route":"/companies/da-novo/"}]}}